GlassScriptPhysician profile
Frank P Matteace
NPI 1417925660
$8,771.02
in general payments reported to CMS, 2019-2025
23 companies · $606 in 2025
The $606 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,759 · 2020: $1,634 · 2021: $1,480 · 2022: $1,021 · 2023: $1,060 · 2024: $1,211 · 2025: $606.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,877.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,877.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $4,463.59 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Janssen Pharmaceuticals, INC | $1,014.62 | 2019-2021 | |
| Novo Nordisk INC | $788.10 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| E.R. Squibb & Sons, L.L.C. | $655.72 | 2019-2021 | |
| Pfizer INC. | $432.78 | 2019-2023 | |
| Abbvie INC. | $271.37 | 2020-2024 | |
| Amgen INC. | $139.73 | 2020-2023 | Otezla |
| Neurelis, INC. | $125.00 | 2021 | |
| Merck Sharp & Dohme LLC | $104.61 | 2019-2020 | |
| Exact Sciences Corporation | $99.05 | 2023-2025 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $93.99 | 2020 | |
| Lilly USA, LLC | $90.97 | 2019-2024 | Mounjaro |
| Kowa Pharmaceuticals America, INC. | $83.71 | 2019-2020 | |
| Amarin Pharma, INC. | $73.98 | 2019-2020 | |
| Astellas Pharma US INC | $69.08 | 2019-2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $49.41 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.94 | 2019 | |
| Glaxosmithkline, LLC. | $41.26 | 2020 | |
| Sunovion Pharmaceuticals INC. | $38.85 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.97 | 2019 | |
| Indivior INC. | $28.13 | 2019-2020 | |
| Shire North American Group INC | $15.00 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.16 | 2024 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Matteace listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.